Drugs / F5 TCR transgenic cells
F5 TCR transgenic cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00910650 | Oct 2009 → May 2019 | metastatic melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F5 TCR transgenic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00910650 ↗ |
| Known as | MART-1 F5 TCR transgenic T cells | “After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v.” NCT00910650 ↗ |
| Known as | MART-1 peptide pulsed dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00910650 ↗ |
| Modality | Cell therapy | “adoptive transfer of autologous PBMC transduced with the MSGV1-F5AfT2AB retroviral vector” NCT00910650 ↗ |
| Route | Intravenous | “MART-1 F5 TCR transgenic T cells infused i.v.” NCT00910650 ↗ |